Advanced Cardiovascular Risk Management through Metabolic Recomposition in South Delhi
Metabolic Recomposition Programme
In the landmark SELECT trial, semaglutide reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established heart disease — benefit that held independent of how much weight was lost. This is the protocol most weight loss clinics in Delhi don't run, because it isn't really a weight loss protocol.
Physician-Led Programme
Evidence-Based Indication
Monthly Lab-Backed Reports
Greater Kailash I, New Delhi
Most GLP-1 conversations in Delhi start and end with appetite and the number on the scale. But the SELECT cardiovascular outcomes trial — over 17,000 adults across 41 countries, with established cardiovascular disease and no diabetes — found something more specific: semaglutide reduced cardiovascular death, heart attack, and stroke by 20%, and this protective effect appeared largely independent of how much weight a person actually lost. In March 2024, this led to FDA approval specifically for cardiovascular risk reduction in adults with overweight or obesity and established heart disease.
Recompose Health, operating out of Greater Kailash I, runs this as a distinct clinical pathway — for patients with known cardiovascular disease (a prior heart attack, stroke, or diagnosed coronary or peripheral artery disease) who carry excess weight, where the goal is risk reduction first and weight management second, under careful physician and cardiology-coordinated supervision.
Established Cardiovascular Disease
A prior heart attack, stroke, or diagnosed coronary, carotid, or peripheral artery disease.
Overweight or Obese, Aged 45 or Above
BMI 27 or above, with or without a formal diabetes diagnosis.
Already Under Cardiology Care
Currently on standard cardiac medications and want this evaluated as an addition under coordinated care, not in isolation.
Want the Evidence Explained Properly
You've heard about cardiac benefits of GLP-1 therapy and want a physician to walk you through whether you actually qualify.
Most clinics prescribe GLP-1 for the scale. We can run it as a specific, evidence-based cardiovascular risk reduction protocol.
Risk Reduction Is the Goal, Not Just the Scale
Treatment success is measured by cardiovascular risk markers and clinical context, not only by kilograms lost.
Coordinated With Your Cardiac Care
We work alongside your existing cardiologist and medications, not as a standalone weight clinic operating in isolation from your cardiac history.
A Dedicated Care Coordinator
Your care coordinator tracks every lab and clinical marker, flags abnormal results immediately, and follows up personally if you miss a check-in.
The Monthly Combined Report
A single visual document tracking weight, lipids, blood pressure, and metabolic markers together — useful documentation to share with your cardiologist.
True Multidisciplinary Care
A metabolic physician, respiratory specialist, dietician, and psychologist working from one shared plan with appropriate caution around your cardiac status.
WhatsApp-Native Journey
Weekly check-ins and your monthly report — delivered where you already are, with clear escalation if anything needs urgent attention.
1 | Discovery Consultation A full clinical assessment of your cardiovascular history, current cardiac medications, BMI, and comorbidities. We discuss whether you fit the evidence-based criteria for this indication and explain pricing transparently. |
2 | Baseline Labs & Cardiac History Review Full lipid panel, HbA1c, fasting glucose, kidney function, blood pressure monitoring, and a review of existing cardiac investigations and reports. You are added to your private WhatsApp care journey. |
3 | Treatment Initiation GLP-1 therapy initiated where clinically appropriate, alongside your first dietician and psychologist sessions. Weekly check-ins begin immediately, with closer monitoring given your cardiac history. |
4 | Monthly Metabolic & Cardiac Risk Review Repeat labs, dose adjustment, and your first Monthly Combined Specialist Report — tracking the markers most relevant to your cardiovascular risk profile. |
5 | Consolidation & Long-Term Handoff Medication review, final labs and risk profile comparison, and a structured handoff into long-term cardiometabolic maintenance, with documentation shared with your cardiologist where useful. |
Lead Physician
GLP-1 initiation, dose titration, clinical oversight, and coordination with your cardiology team where relevant.
Respiratory & Sleep Specialist
Sleep apnoea assessment where indicated, given its well-documented link to cardiovascular risk.
Dedicated Dietician
Monthly sessions building a heart-healthy eating plan aligned with your cardiac dietary requirements.
Clinical Psychologist
Behavioural support for the anxiety and lifestyle adjustment that often follow a cardiac event or diagnosis.
Every tier is physician-led. Given the cardiac context, most patients in this programme are placed in Advanced or Precision — we will help you decide at your discovery consult.
Essential
3-Month Programme
For lower-complexity cases being evaluated for this pathway. Includes physician consults, baseline labs, and monthly dietician sessions.
Most Chosen
Advanced
6-Month Programme
For confirmed cardiovascular disease with overweight or obesity. Adds GLP-1 medication management, psychologist support, and DEXA body composition tracking to the full clinical team.
Precision
8-Month Programme
For complex cardiovascular risk profiles, multiple comorbidities, or significant prior cardiac events. Adds Fibroscan, monthly specialist concalls, organ monitoring, and the full Combined Specialist Report suite.
GLP-1 medication is billed separately as prescribed. Exact pricing is shared transparently at your discovery consultation.
Cardiovascular Risk Markers
Full lipid panel, blood pressure, and waist circumference — the marker most closely associated with cardiovascular benefit in the SELECT trial.
Metabolic Markers
HbA1c, fasting glucose, liver enzymes, and kidney function — tracked monthly alongside your cardiac risk profile.
Body Composition
Weight, BMI, and DEXA body composition — tracked as supporting context, not the primary success measure for this pathway.
Recompose Health
Greater Kailash I, Greater Kailash, New Delhi, Delhi 110048
Book a discovery consultation to discuss your cardiovascular history, find out whether this evidence-based pathway is appropriate for you, and get transparent pricing — no obligation, no pressure.
GLP-1 receptor agonist therapy for cardiovascular risk reduction is appropriate only for specific patients with established cardiovascular disease and overweight or obesity, as determined through individualised evaluation by a qualified physician, and should always be coordinated with the patient's treating cardiologist. This therapy is an adjunct to, not a replacement for, standard cardiac medications and care, which must never be stopped or altered without explicit guidance from the prescribing or treating physician. The cardiovascular outcomes referenced are drawn from published clinical trial data and may not apply to every individual. This page is for informational purposes and does not constitute medical advice; any decision regarding cardiac risk management must be made in consultation with the patient's cardiologist and treating physician.
We've compiled a list of the most frequently asked questions to help you find the information you need quickly and easily.
